혈당 모니터링 시스템 시장은 2024년 121억 2,000만 달러로 추정됩니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 7.72%의 연평균 복합 성장률(CAGR)로 성장하여 2030년에는 188억 9,000만 달러에 달할 것으로 예상됩니다.
혈당 모니터링 시스템 시장은 당뇨병, 내당능 이상 등 생활습관병 유병률 증가, 주요 기업의 제품 출시 및 승인 증가, 저침습적 기술에 대한 선호도 증가 등으로 빠르게 성장하고 있으며, 2024년부터 2030년까지 혈당 모니터링 시스템 수요를 크게 견인할 것으로 예상됩니다. 수요를 크게 견인할 것으로 예상됩니다.
국제당뇨병연맹(International Diabetes Federation)의 데이터(2022년)에 따르면, 2021년 20-79세 성인 5억 3,700만 명, 약 10명 중 1명이 당뇨병을 앓고 있는 것으로 나타났습니다. 이 수치는 2030년에는 6억 4,300만 명으로 증가하고 2045년에는 7억 8,300만 명에 달할 것으로 예상됩니다. 주목할 만한 점은 성인 당뇨병 환자의 75% 이상이 중저소득 국가에 거주하고 있다는 점입니다. 또한, 5억 4,100만 명의 성인이 내당능 장애를 가지고 있어 2형 당뇨병 발병 위험이 높습니다.
혈당 모니터링 시스템은 특히 당뇨병 유병률이 높은 중저소득 국가에서 당뇨병을 관리하고 진행을 예방하는 데 필수적인 도구입니다. 이러한 시스템을 통해 개인은 정기적으로 혈당 수치를 확인하고 관리하여 식단, 운동 및 약물 요법을 적시에 조정할 수 있습니다. 내당능 이상이 있는 사람은 모니터링을 통해 조기 포도당 변동을 식별하고 2형 당뇨병 발병을 예방하기 위한 개입을 지원할 수 있습니다. 이러한 시스템을 효과적으로 사용하면 더 나은 질병 관리, 합병증 감소 및 전반적인 건강 결과를 개선 할 수 있습니다.
이 보고서는 세계 혈당 모니터링 시스템 시장을 조사했으며, 시장 개요와 함께 제품 유형별, 양식별, 최종 사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Blood Glucose Monitoring Systems Market by Product Type (Self-Monitoring Blood Glucose Systems and Continuous Glucose Monitoring Systems), Modality (Wearable and Non-Wearable), End-User (Hospitals, Home Care Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the rising prevalence of lifestyle style disorders and increasing product developmental activities worldwide
The blood glucose monitoring systems market was valued at USD 12.12 billion in 2024, growing at a CAGR of 7.72% during the forecast period from 2024 to 2030 to reach USD 18.89 billion by 2030. The blood glucose monitoring systems market is expanding rapidly due to the rising prevalence of lifestyle style disorders such as diabetes and impaired glucose tolerance, growing product launches and approvals by key players, and a rising preference for minimally invasive techniques that are expected to significantly drive the demand for blood glucose monitoring systems from 2024 to 2030.
Blood Glucose Monitoring Systems Market Dynamics:
According to data from the International Diabetes Federation (2022), in 2021, 537 million adults aged 20-79 were living with diabetes, equating to about 1 in 10 individuals. This number is expected to increase to 643 million by 2030 and reach 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. Additionally, 541 million adults have impaired glucose tolerance, putting them at elevated risk for developing type 2 diabetes.
Blood glucose monitoring systems are essential tools for managing diabetes and preventing its progression, particularly in low- and middle-income countries where the prevalence is high. These systems enable individuals to regularly check and manage their blood glucose levels, allowing for timely adjustments in diet, exercise, and medication. For those with impaired glucose tolerance, monitoring can help identify early glucose fluctuations and support interventions to prevent the onset of type 2 diabetes. Effective use of these systems can lead to better disease management, reducing complications and improving overall health outcomes.
Moreover, companies are amplifying their production of blood glucose monitoring systems and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in January 2024, Medtronic, a global leader in healthcare technology, announced CE Mark approval for the MiniMed(TM) 780G system with Simplera Sync(TM), a disposable, all-in-one continuous glucose monitor that required no fingersticks or overtape. Simplera Sync(TM) featured an improved user experience with a simple, two-step insertion process.
Therefore, all the factors stated above collectively will drive the overall blood glucose monitoring systems market during the forecast period from 2024 to 2030.
However, false readings or technical errors can lead to incorrect insulin dosing which is associated with hypoglycaemia or hyperglycaemia, availability of alternative options among others may limit their end-user base, thus acting as key constraints limiting the growth of the blood glucose monitoring systems market.
Blood Glucose Monitoring Systems Market Segment Analysis:
Blood Glucose Monitoring Systems Market by Product Type (Self-Monitoring Blood Glucose Systems and Continuous Glucose Monitoring Systems), Modality (Wearable and Non-Wearable), End-User (Hospitals, Home Care Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of blood glucose monitoring systems, the continuous glucose monitoring systems category is expected to have a significant revenue share in the year 2023. This is due to the key features and widespread application provided by these.
Continuous glucose monitoring systems provide real-time tracking of blood glucose levels by using a small sensor placed under the skin to measure glucose in interstitial fluid. These offer continuous monitoring and can update readings every few minutes, reducing the need for frequent manual checks. Key features include alarms for high or low glucose levels, calibration-free technology, and integration with smartphones and digital health platforms for detailed data analysis and trend visualization.
These systems are especially beneficial for individuals with Type 1 and Type 2 diabetes, helping them achieve better glycemic control, reduce the risk of hypoglycemia, and optimize insulin therapy through integration with insulin pumps or artificial pancreas systems. Additionally, they are widely used in clinical research to analyze glucose patterns and develop new treatment strategies, making them indispensable for personalized diabetes management and improving patient outcomes.
Rising product developmental activities by regulatory bodies will further boost the market for the same. For example, in June 2024, Abbott announced that the US Food and Drug Administration (FDA) approved two new over-the-counter continuous glucose monitoring systems - Lingo(TM) and Libre Rio(TM). These systems were based on Abbott's world-leading FreeStyle Libre(R) continuous glucose monitoring technology.
Therefore, owing to the above-mentioned factors, the demand for the continuous glucose monitoring category upsurges, owing to which the category is expected to witness considerable growth eventually contributing to the overall growth of the blood glucose monitoring systems market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall blood glucose monitoring systems market:
Among all the regions, North America is expected to dominate the blood glucose monitoring systems market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This is driven by the rising cases of diabetes, advancement in blood glucose monitoring systems, regulatory support, and introduction of innovative products by the key market players that are anticipated to significantly propel market growth for blood glucose monitoring systems from 2024 to 2030.
As per the recent data provided by the Centre for Disease Control and Prevention (2024), in 2021, 38.4 million people of all ages, or 11.6% of the US population had diabetes. Blood glucose monitoring systems are essential tools for managing diabetes, helping individuals regularly check and maintain their blood sugar levels. These systems, including finger-stick glucometers and continuous glucose monitors, enable users to track glucose fluctuations throughout the day. This information allows for timely adjustments in diet, physical activity, and medication to maintain optimal blood sugar levels, prevent complications, and manage diabetes effectively.
Additionally, the increasing number of product development activities in the region by the regulatory bodies is further going to accelerate the growth of the blood glucose monitoring systems market. For instance, in August 2024, Medtronic plc, a global leader in healthcare technology, announced the U.S. Food and Drug Administration (FDA) approved its Simplera(TM) continuous glucose monitor (CGM). This approval marked the launch of the company's first disposable, all-in-one CGM, which was half the size of previous Medtronic CGMs.
In addition to this in June 2024, Prevounce Health, a leading provider of remote care management software, devices, and services, announced the launch of its first remote blood glucose monitoring device, the Pylo GL1-LTE. The blood glucose meter was clinically validated and connected to multiple cellular networks to ensure reliable data transmission throughout the US.
Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the blood glucose monitoring systems market.
Blood Glucose Monitoring Systems Market key players:
Some of the key market players operating in the blood glucose monitoring systems market include Medtronic, Abbott, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Dexcom Inc., ARKRAY, Inc., Senseonics, WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG., Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Prodigy Diabetes Care, LLC, Sinocare, Rossmax International Ltd., Menarini Diagnostics s.r.l., Bionime Corporation., Nemaura., and others.
Recent Developmental Activities in the Blood Glucose Monitoring Systems Market:
Key Takeaways from the Blood Glucose Monitoring Systems Market Report Study
Target audience who can be benefited from this Blood Glucose Monitoring Systems Market Report Study
Frequently Asked Questions for the Blood Glucose Monitoring Systems Market:
The blood glucose monitoring systems are used at home or in health care settings to measure/monitor the amount glucose level in the blood. There are two types of blood glucose monitors available in the market - self-monitoring blood glucose monitoring systems and continuous glucose monitoring systems.
The blood glucose monitoring systems market was valued at USD 12.12 billion in 2024, growing at a CAGR of 7.72% during the forecast period from 2024 to 2030 to reach USD 18.89 billion by 2030.
The blood glucose monitoring systems market is expanding rapidly due to the rising prevalence of lifestyle style disorders such as diabetes and impaired glucose tolerance, growing product launches and approvals by key players, and a rising preference for minimally invasive techniques that are expected to significantly drive the demand for blood glucose monitoring systems from 2024 to 2030.
Some of the key market players operating in the blood glucose monitoring systems market are Medtronic, Abbott, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Dexcom Inc., ARKRAY, Inc., Senseonics, WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG., Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Prodigy Diabetes Care, LLC, Sinocare, Rossmax International Ltd., Menarini Diagnostics s.r.l., Bionime Corporation., Nemaura., and others.
Among all the regions, North America is estimated to hold a significant revenue share in the blood glucose monitoring systems market. This is driven by the rising cases of diabetes, advancement in blood glucose monitoring systems, regulatory support, and introduction of innovative products by the key market players that are anticipated to significantly propel market growth for blood glucose monitoring systems from 2024 to 2030.